Literature DB >> 15100164

Role of serotonin in the pathophysiology of the irritable bowel syndrome.

Michael D Crowell1.   

Abstract

The irritable bowel syndrome (IBS) is a complex disorder that is associated with altered gastrointestinal motility, secretion, and sensation. Serotonin (5-HT) is an important neurotransmitter and paracrine signalling molecule in the gastrointestinal tract. 5-HT release from enterochromaffin (EC) cells initiates peristaltic, secretory, vasodilatory, vagal and nociceptive reflexes. The enteric nervous system (ENS) comprises a semiautonomous effector system that is connected to the central autonomic network. Parasympathetic and sympathetic nerves modulate the ENS via afferent and efferent communications. Ongoing, bidirectional brain-gut interactions involving 5-HT pathways occur that significantly influence the effector systems. Altered 5-HT signalling may lead to both intestinal and extraintestinal symptoms in IBS. 5-HT directly and indirectly affects intestinal motor and secretory function and abnormalities may lead to either constipation or diarrhea. 5-HT modulates sensation and perception of visceral stimulation at peripheral and central sites. Therapeutic agents targeting altered 5-HT signalling may provide new, effective treatments for patients with IBS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100164      PMCID: PMC1574906          DOI: 10.1038/sj.bjp.0705762

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  102 in total

1.  Effects of serotonin on intestinal secretion and motility.

Authors:  Robin C. Spiller
Journal:  Curr Opin Gastroenterol       Date:  2001-03       Impact factor: 3.287

Review 2.  Neurotransmitters in neuronal reflexes regulating intestinal secretion.

Authors:  H J Cooke
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

3.  Towards a reduction of rectal pain?

Authors:  D Grundy
Journal:  Neurogastroenterol Motil       Date:  2002-06       Impact factor: 3.598

Review 4.  The irritable bowel syndrome: review and a graduated multicomponent treatment approach.

Authors:  D A Drossman; W G Thompson
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

5.  Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.

Authors:  B Coffin; J-P Farmachidi; P Rueegg; A Bastie; D Bouhassira
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

Review 6.  Neurohumoral control of gastrointestinal motility.

Authors:  M B Hansen
Journal:  Physiol Res       Date:  2003       Impact factor: 1.881

7.  The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation.

Authors:  P G Farup; N Hovdenak; S Wetterhus; O J Lange; O Hovde; R Trondstad
Journal:  Scand J Gastroenterol       Date:  1998-02       Impact factor: 2.423

Review 8.  Cilansetron. Solvay.

Authors:  G Stacher
Journal:  Curr Opin Investig Drugs       Date:  2001-10

9.  5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.

Authors:  J R Grider; A E Foxx-Orenstein; J G Jin
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome.

Authors:  J Steens; P J Van Der Schaar; C Penning; J Brussee; A A M Masclee
Journal:  Neurogastroenterol Motil       Date:  2002-06       Impact factor: 3.598

View more
  79 in total

1.  Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome.

Authors:  S Mahurkar; C Polytarchou; D Iliopoulos; C Pothoulakis; E A Mayer; L Chang
Journal:  Neurogastroenterol Motil       Date:  2015-12-16       Impact factor: 3.598

Review 2.  Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?

Authors:  Laura Noddin; Michael Callahan; Brian E Lacy
Journal:  MedGenMed       Date:  2005-08-29

Review 3.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

4.  Rare Variants of the Serotonin Transporter Are Associated With Psychiatric Comorbidity in Irritable Bowel Syndrome.

Authors:  Ruth Kohen; Julia H Tracy; Eric Haugen; Kevin C Cain; Monica E Jarrett; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2016-02-24       Impact factor: 2.522

Review 5.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

6.  Comparison of electroacupuncture and moxibustion on brain-gut function in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled trial.

Authors:  Ji-meng Zhao; Jin-hua Lu; Xiao-jun Yin; Xing-kui Chen; Yue-hua Chen; Wei-jun Tang; Xiao-ming Jin; Lu-yi Wu; Chun-hui Bao; Huan-gan Wu; Yin Shi
Journal:  Chin J Integr Med       Date:  2015-04-06       Impact factor: 1.978

Review 7.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 8.  What goes around comes around: novel pharmacological targets in the gut-brain axis.

Authors:  Camila González-Arancibia; Jorge Escobar-Luna; Camila Barrera-Bugueño; Camilo Díaz-Zepeda; María P González-Toro; Loreto Olavarría-Ramírez; Francesca Zanelli-Massai; Martin Gotteland; Javier A Bravo; Marcela Julio-Pieper
Journal:  Therap Adv Gastroenterol       Date:  2016-02-17       Impact factor: 4.409

9.  The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology.

Authors:  Tara J Taylor; Nader N Youssef; Ravi Shankar; David E Kleiner; Wendy A Henderson
Journal:  BMC Res Notes       Date:  2010-10-21

10.  Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort.

Authors:  Gerard Clarke; Peter Fitzgerald; John F Cryan; Eugene M Cassidy; Eamonn M Quigley; Timothy G Dinan
Journal:  BMC Gastroenterol       Date:  2009-01-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.